The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience
Peripheral T cell lymphomas (PTCL) are a rare and heterogeneous group of aggressive non-Hodgkin lymphomas, showing a generally poor prognosis. In this retrospective analysis, we aimed to investigate the impact of autologous stem cell transplantation (autoSCT) in PTCL.
A retrospective analysis of 58 consecutive unselected PTCL patients aged 21–71 years undergoing autoSCT as first-line consolidation as well as in the relapse setting was performed.
The median follow-up time was 67 months. A 5-year overall survival (OS) of 53% and a 5-year progression-free survival (PFS) after autoSCT of 44% was achieved. The overall relapse rate after autoSCT was 50%. On multivariate analysis, standard baseline characteristics such as age, disease stage and international prognostic index (IPI) score failed to predict outcome in our cohort. First-line treatment with autoSCT was not associated with a benefit in OS when compared to patients receiving autoSCT at relapse. Notably, autoSCT seemed to be a suitable approach even for older transplant-eligible patients (aged ≥ 60 years), with a similar 5-year OS of 49% when compared to younger patients.
Our study suggests that autoSCT can achieve long-term survival in PTCL patients even after relapse and should also be considered for eligible older patients.
KeywordsPTCL T cell lymphoma Non-Hodgkin lymphoma Autologous stem cell transplantation AutoSCT
No Funding was received for this study.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
- Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, Kanz L (1992) Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin [see comments]. Blood 79:1193–1200Google Scholar
- d’Amore F et al (2006) Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T cell lymphomas (PTCL)-a phase II Study of the Nordic Lymphoma Group (NLG). Blood 108(11):401Google Scholar
- Haas R et al (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787–3794Google Scholar
- Kharfan-Dabaja MA et al (2017) Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 23:1826–1838CrossRefGoogle Scholar